Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check44 days agoChange DetectedThe page has been updated to reflect the latest version as v2.16.0, replacing the previous version v2.15.2. Additionally, the phrasing regarding the last update has been changed from 'Last Update Posted (Estimated)' to simply 'Last Update Posted'.SummaryDifference0.6%
Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.